Effect of dopamine agonists on lactotroph adenomas of the human pituitary

Endocrine Pathology

Volumn 11, Issue 4, 2000, Pages 341-352

  Stefaneanu, Lucia ^d   Kovacs, Kalman ^e   Scheithauer, Bernd W ^a   Kontogeorgos, George ^b   Riehle, Darren L ^a   Sebo, Thomas J ^a   Murray, David ^e   Vidal, Sergio ^e   Tran, Ami ^e   Buchfelder, Michael ^c   Fahlbusch, Rudolf ^c  

^a MAYO CLINIC   (United States)

^b KAT HOSPITAL   (Greece)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e NONE

Author keywords

Adenomas; Dopamine agonists; Pituitary; Proliferation markers; Vasculature

Indexed keywords

ARANIDIPINE; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROTEIN P27; QUINAGOLIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; INVOLUTION; MALE; MICROVASCULATURE; MITOSIS INDEX; PLOIDY; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION;

EID: 17744388967     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:11:4:341     Document Type: Article

References (56)

1. 1. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240, 1992.
2. 2. Ciccarelli E, Miola C, Grottoli S, Avataneo T, Lancranjan I, Camanni F. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. J Clin Endocrinol Metab 76:484-488, 1993.
3. 3. Tabarin A, Catargi B. Treatment of macroprolactinomas with quinagolide (Norprolac). Annu d'Endocrinol 58:87-94, 1997.
4. 4. Lloyd HM, Meares JD, Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 255:497-498, 1975.
5. 5. Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: a histological, immuno-cytochemical, ultrastructural and morphometric study. J Clin Endocrinol Metab 55: 1178-1183, 1982.
6. 6. Wood DF, Johnston JM, Johnston DG. Dopamine, the dopamine D2 receptor and pituitary tumours. Clin Endocrinol 35:455-466, 1991.
7. 7. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17:489-503, 1990.
8. 8. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984.
9. 9. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wein) 138:1449-1455, 1996.
10. 10. Losa M, Franzin A, Mortini P, Terreni MR, Mangili F, Giovanelli M. Usefulness of markers of cell proliferation in the management of pituitary adenomas. Clin Sci 95:29-135, 1998.
11. 11. Sallinen PK, Haapasalo HK, Visakoripi T, Helen PT, Rantala IS, Isola JJ, Helin HJ. Prognostification of astrocytorna patient survival by Ki-67 (MIB-1), PCNA, and S phase fraction using archival paraffin-embedded samples. J Pathol 174:275-282, 1994.
12. 12. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99-106, 1996.
13. 13. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17:470-471, 1999.
14. 14. Sherr CJ. Cancer cell cycles. Science 274: 1672-1677, 1996.
15. kip1. Cell 85:721-732, 1996.
16. kip1-deficient mice. Cell 85:733-744, 1996.
17. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996.
18. kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323, 1999.
19. kip1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154:119-125, 1999.
20. kip1 expression is correlated with increased cell proliferation but not expression of p21waf1 and p53 and human papillomavirus infection in benign and malignant tumours of sinonasal regions. Histopathology 35:55-64, 1999.
21. kip1 protein. Am J Surg Pathol 23:288-295, 1999.
22. 22. Nakzumi H, Sasano H, Iino K, Ohashi Y, Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 11:1165-1170, 1998.
23. 23. Reed JC, Miyashita T, Takayama S,et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23-32, 1996.
24. 24. Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A. Apoptosis in human pituitary adenomas: a morphological and in-situ end-labeling study. Mod Pathol 10:921-926, 1997.
25. 25. Kulig E, Jin L, Xiang Q, et al. Apoptosis in nontumorous and neoplastic human pituitaries. Expression of the BCL-2 family of proteins. Am J Pathol 154:767-774, 1999.
26. 26. Green VL, White MC, Hipkin LJ, Jeffreys RV, Foy PM, Atkin SL. Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Eur J Endocrinol 136:382-387, 1997.
27. 27. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990.
28. 28. Monschke F, Muller WU, Winkler U, Steffer C. Cell proliferation and vascularization in human breast carcinomas. Int J Cancer 49:812-815, 1991.
29. 29. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 10:302-313, 1993.
30. 30. Barnhill RL, Fandrey K, Levy MA, Mihm MC, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 67:331-337, 1992.
31. 31. Dinh TV, Hannigan EV, Smith ER, Hove MJ, Chopra V, To T. Tumor angiogenesis as a predictor of recurrence in stage Ib squamous cell carcinoma of the cervix. Obst Gynecol 87:751-754, 1996.
32. 32. Jugenburg M, Kovacs K, Jugenburg I, Scheithauer BW. Angiogenesis in endocrine neoplasms. Endocr Pathol 8:259-272, 1997.
33. 33. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159-1162, 2000.
34. 34. Jakubowski J. Blood Supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen-induced adenomatous hyperplasia. Br J Neurosurg 9:331-345, 1995.
35. 35. Pressman N J. Markovian analysis of cervical cell images. J Histochem Cytochem 24:138-144, 1976.
36. 36. Rengachary SS, Tomita T, Jefferies B, Watanabe I. Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242-251, 1982.
37. 37. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab 59:463-479, 1983.
38. 38. Ekramullah SM, Saitoh Y, Ohnishi T, Arita N, Taki T, Hayakawa T. Effects of bromocriptine on staining indices of Ki-67 and proliferating cell nuclear antigen and nucleolar organizer region number in pituitary adenomas, Neurol Med Chir 35:221-226, 1940.
39. 39. Burger PC, Shibata T, Kleihues P. Proliferation markers for neoplasms of the nervous system. In: Advances in Immunohistochemistry, DeLellis RA (ed), New York, Raven Press, 1988; 302-316.
40. 40. Thapar K, Yamada Y, Scheithauer BW, Kovacs K, Yamada S, Stefaneanu L. Assessment of mitotic activity in pituitary adenomas and carcinomas. Endocr Pathol 7:215-221, 1996.
41. 41. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T. Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase a monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neruopathol 84:178-183, 1992.
42. 42. Stefaneanu L, Kovacs K, Horvath E, et al. In-situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J Clin Endocrinol Metab 78:83-88, 1993.
43. 43. Lloyd RV, Cano M, Landerfeld TD. The effects of estrogens on tumor growth and on prolactin and growth hormone mRNA expression in rat pituitary tissues. Am J Pathol 133:397-406, 1988.
44. 44. Waterman ML, Adler S, Nelson C, Greene GL, Evans R, Rosenfeld MG. A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. Mol Endocrinol 2:14-21, 1988.
45. 45. Bamberger CM, Fehn M, Bamberger AM, et al. Reduced expression levels of the cell-cycle inhibitor p27 in human pituitary adenomas. Eur J Endocrinol 140:250-255, 1999.
46. kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509-519, 1997.
47. 47. Tanaka C, Yoshimoto K, Yang P, et al. Infrequent mutations of p27kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab 82:3141-3147, 1997.
48. 48. Yin D, Kondo S, Takeuchi J, Morimura T. Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 339:73-75, 1994.
49. 49. Drewett N, Jacobi JM, Willgoss DA, Lloyd HM. Apoptosis in the anterior pituitary gland of the rat: studies with estrogen and bromocriptine. Neuroendocrinology 57:89-95, 1993.
50. 50. Weidner N, Semple JP, Welch WR, Folkman JF. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
51. 51. Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48:47-57, 1996.
52. 52. Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC. Effects of quinagolide (CV205-502), a selective D2-agonist, on vascular reactivity in patients with prolactin-secreting adenoma. Clin Endocrinol 43: 49-53, 1995.
53. 53. Kemeny AA, Jakubowski JA, Pasztor Z, Jefferson AA, Wojcikiewicz R. Reduction of blood flow in the adenohypophysis of rats by bromocriptine. J Neurosurg 63:120-124, 1985.
54. 54. Kemeny AA, Jakubowski J, Stawowy A, Smith C, Timperley WR. Changes of blood flow in oestrogen induce hyperplastic anterior lobe following bromocriptine administration. Br J Neurosurg 1:243-250, 1987.
55. 55. Kobayashi Y, Amenta F, Ricci A, Hattori K. Localisation of dopamine D1-like and D2-like receptors in the pulmonary vasculature. Hypertension Res 1:S153-156, 1995.
56. 56. Kobayashi Y, Cavallotti D, Ricci A, Amenta F. Localisation of dopamine D2-like receptors in pulmonary artery of the human and rabbit but not of the rat. Eur J Pharmacol 261:229-236, 1994.